A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
Status:
Completed
Trial end date:
2017-05-15
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of the study drug prexasertib in
combination with ralimetinib in participants with advanced or metastatic cancer.